Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Trends in post-relapse survival in Hodgkin lymphoma

Talha Badar • 3 Jun 2020
EHA 2020
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Nivolumab

Talha Badar, MD, Medical College of Wisconsin, Milwaukee, WI, discusses trends in post-relapse survival in classic Hodgkin lymphoma. Specifically discussed is the advent of novel agents such as brentuximab vedotin and the resulting improvements in outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Talha Badar

4:38
Blinatumomab vs inotuzumab ozogamicin for ALL
Talha Badar • 2 Jun 2020
2:12
The impact of immuno-oncology on ALL outcomes
Talha Badar • 2 Jun 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals